prazosin has been researched along with Coronary Disease in 114 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease." | 9.09 | [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| " Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)." | 9.07 | Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991) |
| "This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)." | 9.07 | Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991) |
| "This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting." | 9.07 | A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 9.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| "Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients." | 9.06 | Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 9.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months." | 7.68 | Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991) |
| "Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension." | 7.67 | Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988) |
| "Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension." | 7.67 | Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988) |
| "Short- and long-term hemodynamic and clinical responses to sequential therapy with prazosin (15 mg/day for 3 to 12 weeks) and captopril (75 to 300 mg/day for 2 to 15 weeks) were compared in 22 patients with severe chronic congestive heart failure." | 7.67 | Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The effect of prazosin in congestive heart failure was assessed in 10 patients (age 39--69) years) with ischemic heart disease or cardiomyopathy in functional class II-IV (NYHA)." | 7.66 | Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure. ( Lund-Johansen, P; Ohm, OJ; von der Lippe, G, 1981) |
| "We compared cardiocirculatory actions of nitroprusside (NP) to prazosin (PZ) in eleven chronic coronary patients with refractory congestive heart failure." | 7.66 | Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure. ( Awan, NA; Mason, DT; Miller, RR, 1978) |
| "Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates." | 7.66 | Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy. ( Amsterdam, EA; DeMaria, AN; Laslett, LJ; Mason, DT, 1978) |
| "The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease." | 7.65 | Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 5.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| " This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease." | 5.09 | [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| " Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)." | 5.07 | Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991) |
| "The antihypertensive efficacy and safety of doxazosin (once daily) and prazosin (twice daily) were compared in patients with mild or moderate essential hypertension (diastolic blood pressure [DBP] 95 to 114 mm Hg) not adequately controlled by diuretics and beta-blockers." | 5.07 | A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics. ( de Planque, BA, 1991) |
| "This study investigated the safety and efficacy of doxazosin treatment in a large population of patients (n = 336) with essential hypertension and assessed the effect of doxazosin on the serum lipid profile and the calculated risk of developing coronary heart disease." | 5.07 | Clinical experience with doxazosin in general medical practice in New Zealand. ( Maslowski, AH, 1991) |
| "This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)." | 5.07 | Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991) |
| "This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting." | 5.07 | A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991) |
| "This study was designed to investigate the efficacy and toleration of once-daily doxazosin in the treatment of essential hypertension (sitting diastolic blood pressure 95 to 115 mm Hg) in a general medical practice." | 5.07 | Clinical experience with doxazosin in general medical practice in The Netherlands. ( Harmse, DP, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 5.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| "The efficacy and toleration of doxazosin and atenolol were compared over a 52-week period in a double-blind, multicenter study of 228 patients with mild-to-moderate hypertension." | 5.06 | Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients. ( Daae, L; Talseth, T; Vatle, S; Westlie, L, 1988) |
| "Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients." | 5.06 | Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 5.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "Prazosin (Minipress) monotherapy was given to 152 patients with essential hypertension for one year in a multi-center study involving 13 hospitals and university clinics." | 3.68 | [The anti-lipidemic effect of Minipress]. ( Dudás, M; Farsang, C; Földes, I; Iványi, J; Pados, G, 1990) |
| "Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months." | 3.68 | Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991) |
| "Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension." | 3.67 | Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988) |
| "The antihypertensive efficacy, lipid effects, and safety of doxazosin, a selective alpha 1-inhibitor for the reduction of coronary heart disease (CHD) risk in hypertensive patients, was assessed in a general medical practice setting." | 3.67 | Clinical experience with doxazosin in general medical practice. ( Rosenthal, J, 1988) |
| "Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension." | 3.67 | Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988) |
| "Short- and long-term hemodynamic and clinical responses to sequential therapy with prazosin (15 mg/day for 3 to 12 weeks) and captopril (75 to 300 mg/day for 2 to 15 weeks) were compared in 22 patients with severe chronic congestive heart failure." | 3.67 | Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The system release of prazosin confirms the good efficacy and tolerance of Alpress in the hypertension treatment." | 3.67 | [Efficacy, tolerance and incidence of risk factors of Alpress in the treatment of arterial hypertension]. ( Neimann, JL, 1989) |
| "Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates." | 3.66 | Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy. ( Amsterdam, EA; DeMaria, AN; Laslett, LJ; Mason, DT, 1978) |
| "We compared cardiocirculatory actions of nitroprusside (NP) to prazosin (PZ) in eleven chronic coronary patients with refractory congestive heart failure." | 3.66 | Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure. ( Awan, NA; Mason, DT; Miller, RR, 1978) |
| "The effect of prazosin in congestive heart failure was assessed in 10 patients (age 39--69) years) with ischemic heart disease or cardiomyopathy in functional class II-IV (NYHA)." | 3.66 | Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure. ( Lund-Johansen, P; Ohm, OJ; von der Lippe, G, 1981) |
| "The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease." | 3.65 | Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977) |
| "Because coronary heart disease is known to have many causes, primary preventive therapy must logically go beyond the relatively simple goal of lowering blood pressure." | 2.66 | Effects of oral antihypertensive agents on blood lipid levels. ( Leren, P, 1986) |
| "Treatment with prazosin for one month also reduced systemic vascular resistance by 8%, renal vascular resistance increased by 20%, and renal blood flow and the percentage of the cardiac output going to the kidney fell by 14% and 26%." | 2.66 | The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, P; Sutton, G, 1986) |
| " It is readily absorbed, with high bioavailability and a relatively long plasma half-life, neither of which property is influenced by age." | 2.38 | Clinical pharmacotherapeutics of doxazosin. ( Taylor, SH, 1989) |
| "Doxazosin appears to inhibit the development of CHD on two fronts." | 2.38 | Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. ( Pool, JL, 1991) |
| "When nifedipine was compared with isosorbide dinitrate in a randomized crossover, double-blind trial in patients with coronary artery spasm, both drugs were shown to be efficacious and neither was superior." | 2.37 | Large vessel coronary vasospasm: diagnosis, natural history and treatment. ( Conti, CR, 1985) |
| "An arterial stenosis that decreased coronary pressure to 40-42 mmHg resulted in a decrease of myocardial blood flow to 1." | 1.28 | Coronary arteriolar vasoconstriction in myocardial ischaemia: coronary vasodilator reserve during ischaemia. ( Bache, RJ; Laxson, DD, 1990) |
| "4." | 1.28 | Enhanced alpha-adrenoceptor responsiveness and receptor number during global ischaemia in the Langendorff perfused rat heart. ( Butterfield, MC; Chess-Williams, R, 1990) |
| "When adenosine release was attenuated by administration of prazosin (4 micrograms/kg/min i." | 1.28 | Endogenous adenosine blunts beta-adrenoceptor-mediated inotropic response in hypoperfused canine myocardium. ( Hori, M; Inoue, M; Kamada, T; Kitabatake, A; Kitakaze, M; Sato, H; Takashima, S, 1992) |
| " Phentolamine effected a partial dose-related inhibition of flow reductions; however, prazosin and yohimbine, given separately or in combination, failed to produce any significant effect despite an alpha-blocking action equivalent to or greater than that of phentolamine (alpha-agonist dose-response studies)." | 1.27 | Influence of alpha-adrenergic blockade on platelet-mediated thrombosis in stenosed canine coronary arteries. ( Bolli, R; Brandon, TA; Mace, ML; Weibaecher, DG, 1985) |
| "Systemic hypertension is a common clinical problem in the elderly." | 1.27 | Geriatric hypertension: antihypertensive therapy in coronary artery disease. ( Gonzalez, DG; Ram, CV, 1987) |
| "During coronary reperfusion, arrhythmias did not differ in control and treated groups." | 1.27 | Effect of alpha-adrenergic blockade on arrhythmias induced by acute myocardial ischemia and reperfusion in the dog. ( Bolli, R; Fisher, DJ; Miller, RR; Taylor, AA; Young, JB, 1984) |
| " These results show that the dose-response curve for the inhibitory effect of prazosin on Ca2+ overload is complex, and that adding prazosin coincident with the reperfusion of isolated ischaemic hearts does not attenuate Ca2+ gain." | 1.27 | The protective effect of prazosin on the ischaemic and reperfused myocardium. ( Gordon, M; Nayler, WG; Stephens, DJ; Sturrock, WJ, 1985) |
| "Prazosin treatment also prevented the delayed conduction of paced ventricular complexes entering and exiting the ischemic zone." | 1.27 | Electrophysiologic effects of prazosin during acute myocardial ischemia. ( Lucchesi, BR; Lynch, JJ; Wilber, DJ, 1986) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 1.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| "Initially, the pharmacologic treatment of hypertension consisted mostly of thiazide diuretics, since they were the only agents generally available that were well-tolerated by most patients." | 1.27 | Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension. ( Grimm, RH; Hunninghake, DB, 1986) |
| "Protection from arrhythmias seems to be related to the combined presence of a noncompetitive adrenergic blockade associated with salutary effects on coronary circulation." | 1.27 | The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. ( Schwartz, PJ; Vanoli, E; Zaza, A; Zuanetti, G, 1985) |
| "With prazosin there was a reduction in ventricular filling pressures and rate-pressure product but no change in coronary sinus flow or MVO2." | 1.26 | Vasodilators in heart failure secondary to coronary artery disease. ( Chatterjee, K; Parmley, WW; Rouleau, JL, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (70.18) | 18.7374 |
| 1990's | 34 (29.82) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leren, P | 2 |
| Foss, PO | 1 |
| Helgeland, A | 1 |
| Hjermann, I | 1 |
| Holme, I | 2 |
| Lund-Larsen, PG | 1 |
| Thandroyen, FT | 1 |
| Worthington, MG | 1 |
| Higginson, LM | 1 |
| Opie, LH | 2 |
| Heinecker, R | 1 |
| Sharma, AD | 1 |
| Saffitz, JE | 1 |
| Lee, BI | 1 |
| Sobel, BE | 1 |
| Corr, PB | 2 |
| Shevchenko, VA | 1 |
| Lowenstein, J | 1 |
| Bolli, R | 2 |
| Fisher, DJ | 1 |
| Taylor, AA | 2 |
| Young, JB | 1 |
| Miller, RR | 3 |
| Shayman, JA | 1 |
| Kramer, JB | 1 |
| Kipnis, RJ | 1 |
| Ram, CV | 2 |
| Manno, BV | 1 |
| Iskandrian, AS | 1 |
| Hakki, AH | 1 |
| Bolte, HD | 1 |
| Bush, LR | 1 |
| Campbell, WB | 1 |
| Kern, K | 1 |
| Tilton, GD | 1 |
| Apprill, P | 1 |
| Ashton, J | 1 |
| Schmitz, J | 1 |
| Buja, LM | 1 |
| Willerson, JT | 1 |
| Benfey, BG | 1 |
| Elfellah, MS | 1 |
| Ogilvie, RI | 1 |
| Varma, DR | 1 |
| Sharpe, DN | 1 |
| Coxon, R | 1 |
| Klein, W | 1 |
| Goebel, R | 1 |
| Heusch, G | 2 |
| Deussen, A | 1 |
| Chatterjee, K | 3 |
| Rouleau, JL | 3 |
| Benge, W | 1 |
| Parmley, WW | 2 |
| Hiramatsu, B | 1 |
| Młyński, J | 1 |
| Silke, B | 2 |
| Taylor, SH | 5 |
| von der Lippe, G | 1 |
| Ohm, OJ | 1 |
| Lund-Johansen, P | 1 |
| Hendry, WG | 1 |
| Krishnan, S | 1 |
| Levy, MN | 1 |
| Tamaki, M | 1 |
| Ueda, T | 1 |
| Kageyama, S | 1 |
| Bartolo, M | 1 |
| Pittorino, L | 1 |
| Di Lorenzo, M | 1 |
| Ricci, G | 1 |
| Awan, NA | 2 |
| Mason, DT | 3 |
| Laslett, LJ | 1 |
| DeMaria, AN | 2 |
| Amsterdam, EA | 1 |
| Timio, M | 1 |
| Gentili, S | 1 |
| Pede, S | 1 |
| Schiaroli, M | 1 |
| Maxwell, KS | 1 |
| Neumann, A | 1 |
| Sato, H | 1 |
| Hori, M | 2 |
| Kitakaze, M | 2 |
| Takashima, S | 1 |
| Inoue, M | 1 |
| Kitabatake, A | 2 |
| Kamada, T | 2 |
| Piatak, OA | 1 |
| Yanovskii, GV | 1 |
| Lizogub, VG | 1 |
| de Planque, BA | 1 |
| Grimm, RH | 2 |
| McInnes, GT | 1 |
| Passarelli, P | 1 |
| Galiè, N | 1 |
| Limonetti, P | 1 |
| Branzi, A | 1 |
| Magnani, B | 1 |
| Westby, J | 3 |
| Hexeberg, E | 1 |
| Olweus, J | 1 |
| Myking, OL | 1 |
| Lekven, J | 3 |
| Grong, K | 3 |
| Antani, JA | 1 |
| Antani, NJ | 1 |
| Nanivadekar, AS | 1 |
| Pool, JL | 2 |
| Fauchald, P | 1 |
| Rugstad, HE | 1 |
| Stokke, HP | 1 |
| Langdon, CG | 1 |
| Naber, FB | 1 |
| Talseth, T | 2 |
| Westlie, L | 2 |
| Daae, L | 2 |
| Wessels, F | 1 |
| Maslowski, AH | 1 |
| Silva, H | 1 |
| Fonseca, R | 2 |
| Marshall, D | 1 |
| Bonnet, G | 1 |
| Harmse, DP | 1 |
| Monsalve, P | 1 |
| Vera, O | 1 |
| Pérez Acuña, F | 1 |
| Medina, O | 1 |
| Ostojich, K | 1 |
| López, B | 1 |
| Torres, N | 1 |
| Lugo de Franco, V | 1 |
| Hernandez Hernandez, R | 1 |
| Guerrero Pajuelo, JR | 1 |
| Carvajal, AR | 1 |
| Armas Padilla, MC | 1 |
| Armas de Hernandez, MJ | 1 |
| Barragan, O | 1 |
| Boada Boada, JJ | 1 |
| Kaneko, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, A | 1 |
| Yamazaki, N | 1 |
| Dhalla, NS | 1 |
| Kvitting, P | 2 |
| Birkeland, S | 2 |
| Bache, RJ | 2 |
| Laxson, DD | 2 |
| Lenz, ML | 1 |
| Seitelberger, R | 1 |
| Guth, BD | 1 |
| Ross, J | 1 |
| Rouffy, J | 1 |
| Butterfield, MC | 1 |
| Chess-Williams, R | 1 |
| Kawai, T | 1 |
| Okumura, K | 1 |
| Hashimoto, H | 1 |
| Ito, T | 1 |
| Satake, T | 1 |
| Pados, G | 1 |
| Iványi, J | 1 |
| Földes, I | 1 |
| Dudás, M | 1 |
| Farsang, C | 1 |
| Mohanlal, RW | 1 |
| Mauve, I | 1 |
| van der Valk, L | 1 |
| Bruschke, AV | 1 |
| van der Laarse, A | 1 |
| Galassi, AR | 1 |
| Kaski, JC | 1 |
| Pupita, G | 1 |
| Vejar, M | 1 |
| Crea, F | 1 |
| Maseri, A | 1 |
| Dai, XZ | 1 |
| Homans, DC | 1 |
| Manning, AS | 2 |
| Crome, R | 1 |
| Klein, N | 1 |
| Hearse, DJ | 2 |
| Maguire, ME | 1 |
| Graham, RM | 1 |
| Rosenthal, J | 3 |
| Neimann, JL | 1 |
| Rockhold, FW | 1 |
| Goldberg, MR | 1 |
| Thompson, WL | 1 |
| Burduli, FU | 1 |
| Khadzhidis, PK | 1 |
| Vatsadze, TG | 1 |
| Tabidze, GA | 1 |
| Tamai, J | 1 |
| Iwakura, K | 1 |
| Gotoh, K | 1 |
| Iwai, K | 1 |
| Koretsune, Y | 1 |
| Kagiya, T | 1 |
| Shiga, T | 1 |
| Nakazawa, M | 1 |
| Imai, S | 1 |
| Dillon, JS | 1 |
| Gu, XH | 1 |
| Nayler, WG | 2 |
| Conti, CR | 1 |
| Moulds, RF | 1 |
| Brandon, TA | 1 |
| Mace, ML | 1 |
| Weibaecher, DG | 1 |
| Davey, MJ | 1 |
| Sheridan, DJ | 1 |
| Gonzalez, DG | 1 |
| van den Hogen, AL | 1 |
| Bartels, AC | 1 |
| de Vries, PM | 1 |
| Oe, LP | 1 |
| van Bronswÿk, H | 1 |
| Donker, AJ | 1 |
| Réveillaud, RJ | 1 |
| Fillastre, JP | 1 |
| Zech, P | 1 |
| Castrignano, R | 1 |
| D'Angelo, A | 1 |
| Pati, T | 1 |
| Al Awady, M | 1 |
| Tronca, R | 1 |
| Crepaldi, G | 1 |
| Vatle, S | 1 |
| Mazzola, C | 1 |
| Guerrasio, E | 1 |
| Nechwatal, W | 1 |
| Berger, J | 1 |
| Blumrich, W | 1 |
| Bouzo, H | 1 |
| Brandl, K | 1 |
| Braun, S | 1 |
| Laukaitis, A | 1 |
| Müller, G | 1 |
| Ryba, W | 1 |
| Schreiegg, J | 1 |
| Lindner, UK | 1 |
| von Manteuffel, GE | 1 |
| Stafunsky, M | 1 |
| Englert, RG | 1 |
| Mauersberger, H | 1 |
| Hansson, L | 1 |
| Gordon, M | 1 |
| Stephens, DJ | 1 |
| Sturrock, WJ | 1 |
| Wilber, DJ | 1 |
| Lynch, JJ | 1 |
| Lucchesi, BR | 1 |
| Urbaszek, W | 1 |
| Graf, B | 1 |
| Bölter, C | 1 |
| Zingler, C | 1 |
| Mekat, A | 1 |
| Nabel, HJ | 1 |
| Ernst, B | 1 |
| Kinoshita, K | 1 |
| Braimbridge, MV | 1 |
| Hagestad, EL | 1 |
| Verrier, RL | 1 |
| Packer, M | 1 |
| Medina, N | 1 |
| Yushak, M | 1 |
| Bayliss, J | 2 |
| Canepa-Anson, R | 2 |
| Norell, M | 1 |
| Poole-Wilson, P | 2 |
| Sutton, G | 2 |
| Schwartz, PJ | 2 |
| Vanoli, E | 2 |
| Norell, MS | 1 |
| Reid, C | 1 |
| Hunninghake, DB | 1 |
| Zaza, A | 1 |
| Zuanetti, G | 1 |
14 reviews available for prazosin and Coronary Disease
| Article | Year |
|---|---|
[Treatment of heart failure in ischemic heart disease with beta-adrenostimulators and peripheral vasodilators].
Topics: Adrenergic beta-Agonists; Captopril; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; Hea | 1983 |
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
Right ventricular function: methodologic and clinical considerations in noninvasive scintigraphic assessment.
Topics: Animals; Captopril; Coronary Disease; Echocardiography; Heart; Heart Defects, Congenital; Heart Vent | 1984 |
[Treatment of heart failure with vasodilators].
Topics: Captopril; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Heart Failure; Heart Function Tests; | 1980 |
Antihypertensive therapy: taking lipids into consideration.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1991 |
The value of alpha-blockers in the management of hypertension: a practical view.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; | 1991 |
Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
Topics: Antihypertensive Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Doxazosin; Humans; | 1991 |
Clinical pharmacotherapeutics of doxazosin.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Hemodynamics; Humans; Hypertension; Prazo | 1989 |
Selective alpha 1-adrenergic blockade, lipids, and coronary heart disease risk. Considerations in the treatment of mild hypertension.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Humans; Hypertension; Lipids; Prazosin; Risk Factors | 1989 |
Blood pressure and lipid lowering effects of terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Humans; Hyp | 1989 |
Large vessel coronary vasospasm: diagnosis, natural history and treatment.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aspirin; Coronary Artery Bypass; Coronary | 1985 |
Alpha adrenoceptors--an overview.
Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Catecholamines; Child, Preschool; Coron | 1986 |
Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Dose-Response Relationship, | 1988 |
Implications of doxazosin therapy on risk of coronary heart disease.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Lipoprot | 1988 |
28 trials available for prazosin and Coronary Disease
| Article | Year |
|---|---|
Effect of propranolol and prazosin on blood lipids. The Oslo Study.
Topics: Cerebrovascular Disorders; Cholesterol; Coronary Disease; Drug Antagonism; Drug Therapy, Combination | 1980 |
Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects.
Topics: Aged; Aldosterone; Blood Pressure; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Di | 1982 |
Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study.
Topics: Aged; Captopril; Coronary Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Hu | 1982 |
[Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
Topics: Aged; Coronary Disease; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Prazosin; Prostatic Hype | 1999 |
The influence of adrenoreactive preparations on clinical and haemodynamic parameters in patients with ischaemic heart disease.
Topics: Adult; Angina Pectoris; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Exercise Tes | 1991 |
A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Coronary Disease; Diuretics; Double-Blind Meth | 1991 |
[Comparative effects of doxazosin and enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Enalapril; | 1991 |
Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience.
Topics: Antihypertensive Agents; Blood Pressure; Cholesterol; Coronary Disease; Doxazosin; Female; Heart Rat | 1991 |
Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
Topics: Antihypertensive Agents; Cholesterol; Cohort Studies; Coronary Disease; Doxazosin; England; Family P | 1991 |
An open, noncomparative study of doxazosin in essential hypertension: experience in general practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
Topics: Antihypertensive Agents; Atenolol; Cholesterol; Coronary Disease; Double-Blind Method; Doxazosin; Fe | 1991 |
Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension.
Topics: Antihypertensive Agents; Coronary Disease; Double-Blind Method; Doxazosin; Enalapril; Family Practic | 1991 |
Clinical experience with doxazosin in general medical practice in New Zealand.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Doxazosin in the treatment of essential hypertension in general medical practice in Latin America.
Topics: Antihypertensive Agents; Argentina; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Femal | 1991 |
A multicenter study of doxazosin in the treatment of essential hypertension in France.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; France; | 1991 |
Clinical experience with doxazosin in general medical practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Cholesterol; Coronary Disease; Doxazosin; Echocardiography; F | 1991 |
Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; England; Female; Humans; Hyperten | 1991 |
Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; | 1991 |
[Alpha-1 inhibition. Prevention of coronary risk factors].
Topics: Atenolol; Coronary Disease; Delayed-Action Preparations; Female; Humans; Hypertension; Lipids; Male; | 1990 |
Beneficial effects of pinacidil on blood lipids: comparisons with prazosin and placebo in patients with hypertension. Pinacidil-Prazosin and Pinacidil-Placebo Research Groups, Lilly Research Laboratories.
Topics: Antihypertensive Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; | 1989 |
[Use of prazosin and capoten in the treatment of heart failure in patients with ischemic heart disease].
Topics: Adult; Captopril; Cardiomyopathy, Dilated; Clinical Trials as Topic; Coronary Disease; Hemodynamics; | 1989 |
Effects of oral antihypertensive agents on blood lipid levels.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cl | 1986 |
Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Coronary D | 1988 |
Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pres | 1988 |
A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin.
Topics: Aged; Aldosterone; Captopril; Cardiac Output; Cardiomyopathy, Dilated; Coronary Disease; Double-Blin | 1986 |
Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin.
Topics: Aged; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; F | 1985 |
72 other studies available for prazosin and Coronary Disease
| Article | Year |
|---|---|
Antihypertensive drugs, plasma lipids, and coronary disease.
Topics: Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Coronary Disease; Drug Antagonis | 1980 |
The effect of alpha- and beta-adrenoceptor antagonist agents on reperfusion ventricular fibrillation and metabolic status in the isolated perfused rat heart.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Arterial Occlusive Diseases; Ate | 1983 |
[Frequent errors in the therapy of heart disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biologic | 1982 |
Alpha adrenergic-mediated accumulation of calcium in reperfused myocardium.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium; C | 1983 |
Effects of prazosin on serum lipids in patients with essential hypertension: a review of the findings presented at the Satellite Symposium on coronary heart disease: hypertension and other risk factors, Milan, 1983.
Topics: Adrenergic beta-Antagonists; Benzothiadiazines; Chlorthalidone; Cholesterol; Cholesterol, HDL; Coron | 1984 |
Calcium ions, drug action and the heart--with special reference to calcium antagonist drugs.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channe | 1984 |
Effect of alpha-adrenergic blockade on arrhythmias induced by acute myocardial ischemia and reperfusion in the dog.
Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Carbon Dioxide; Coronar | 1984 |
Increased alpha-adrenergic receptors in ischemic cat myocardium. A potential mediator of electrophysiological derangements.
Topics: Animals; Cats; Coronary Disease; Prazosin; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Rece | 1981 |
The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
Topics: Adenosine Diphosphate; Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Dogs; F | 1984 |
Coronary heart disease: hypertension and other risk factors. Proceedings of a satellite symposium of the first European Meeting on Hypertension.
Topics: Coronary Disease; Humans; Hypertension; Lipid Metabolism; Prazosin; Risk | 1984 |
Anti-arrhythmic effects of prazosin and propranolol during coronary artery occlusion and re-perfusion in dogs and pigs.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Disease; Dogs; Drug Therapy, Combinat | 1984 |
[Effects of acute and chronic vasodilator administration on hemodynamics and catecholamine concentration in chronic left heart failure (author's transl)].
Topics: Blood Pressure; Cardiac Output; Cardiomyopathies; Catecholamines; Coronary Disease; Dopamine; Epinep | 1980 |
The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog.
Topics: Animals; Coronary Circulation; Coronary Disease; Coronary Vessels; Dogs; Electric Stimulation; Heart | 1983 |
Hemodynamic and metabolic effects of vasodilators, nitrates, hydralazine, prazosin and captopril in chronic ischemic heart failure.
Topics: Captopril; Coronary Disease; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Lactates; Myoc | 1981 |
Vasodilators in heart failure secondary to coronary artery disease.
Topics: Cardiac Output; Coronary Disease; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Myocardi | 1982 |
[Effect of prazosin on changes in blood lipids].
Topics: Coronary Disease; Humans; Hyperlipoproteinemia Type IV; Hypertension; Lipoproteins, HDL; Lipoprotein | 1982 |
Pharmacokinetic and haemodynamic studies with prazosin in chronic heart failure.
Topics: Aged; Blood Pressure; Chronic Disease; Coronary Disease; Electrocardiography; Exercise Test; Female; | 1981 |
Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure.
Topics: Adult; Aged; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Male; | 1981 |
Immediate and sustained haemodynamic effects of prazosin during upright exercise in man.
Topics: Coronary Disease; Hemodynamics; Humans; Physical Exertion; Prazosin; Quinazolines | 1981 |
Effects of coronary artery occlusion and reperfusion on the idioventricular rate in anesthetized dogs.
Topics: Analysis of Variance; Animals; Coronary Disease; Disease Models, Animal; Dogs; Heart Block; Heart Ra | 1994 |
The role of prazosin in the management of hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Anesthesia, General; Child; Coronary Disease; Diuretics; Dr | 1977 |
[Flow measurement characteristics in heart patients after the acute and protracted administration of 2 vasoactive drugs: prazosin hydrochloride and isosorbide dinitrate].
Topics: Blood Circulation; Coronary Disease; Humans; Hyperemia; Isosorbide Dinitrate; Prazosin; Quinazolines | 1979 |
Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure.
Topics: Adult; Aged; Blood Circulation; Coronary Disease; Female; Ferricyanides; Heart Failure; Heart Rate; | 1978 |
Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy.
Topics: Aged; Coronary Disease; Digitalis Glycosides; Female; Furosemide; Heart Failure; Humans; Hydralazine | 1978 |
[Prazosin in refractory congestive heart failure].
Topics: Adult; Aged; Coronary Disease; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Male; Middle | 1978 |
Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Blood Pressure; Cardiac Output; Chronic Disease; | 1977 |
Endogenous adenosine blunts beta-adrenoceptor-mediated inotropic response in hypoperfused canine myocardium.
Topics: Adenosine; Animals; Coronary Disease; Dogs; Heart; Isoproterenol; Myocardial Contraction; Prazosin; | 1992 |
Management of coronary heart disease risk factors in hypertensive patients: clinical experience with doxazosin. A symposium. London, England, January 26, 1990. Proceedings.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1991 |
Blood flow regulation during acute regional ischemia in feline hearts: importance of postjunctional alpha 1- and alpha 2-adrenoceptors.
Topics: Adrenergic alpha-Antagonists; Animals; Benzazepines; Catecholamines; Cats; Coronary Circulation; Cor | 1991 |
Prazosin in chronic congestive heart failure due to ischemic heart disease.
Topics: Aged; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up | 1991 |
Stunned myocardium and oxygen free radicals--sarcolemmal membrane damage due to oxygen free radicals.
Topics: Adenosine Triphosphatases; Animals; Calcium; Catalase; Cell Membrane; Coronary Disease; Free Radical | 1991 |
Regional perfusion in hearts with acute coronary artery occlusion and subsequent beta 2- and alpha 1-adrenergic blockade.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cats; Coronary Circulation; Coro | 1990 |
Coronary arteriolar vasoconstriction in myocardial ischaemia: coronary vasodilator reserve during ischaemia.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Constriction, Pathologic; Coronary Circulatio | 1990 |
Hypertension, coronary risk and alpha-blockade.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Fact | 1990 |
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
Topics: Adrenergic alpha-Antagonists; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dox | 1990 |
Alpha 2-adrenergic coronary constriction in ischemic myocardium during exercise.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; | 1990 |
Enhanced alpha-adrenoceptor responsiveness and receptor number during global ischaemia in the Langendorff perfused rat heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Binding Sites; Coronary Disease; Heart Rate; | 1990 |
Alteration of 1,2-diacylglycerol content in ischemic and reperfused heart.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Diglycerides; Dogs; Kinetics; Male; Myocardial Repe | 1990 |
[The anti-lipidemic effect of Minipress].
Topics: Coronary Disease; Drug Evaluation; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertension; Hypo | 1990 |
Does alpha 1-adrenergic blockade influence regional blood flow regulation in hearts with coronary artery occlusion?
Topics: Animals; Atenolol; Cats; Coronary Circulation; Coronary Disease; Doxazosin; Female; Male; Prazosin; | 1989 |
Delayed recovery of homogeneous perfusion distribution in isolated rat heart after vasodilatation induced by alpha 1 adrenoceptor blockade during postischaemic reperfusion.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Doxazosin; L-Lactate Dehydroge | 1989 |
Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X.
Topics: Adult; Angina Pectoris; Clonidine; Coronary Angiography; Coronary Disease; Electrocardiography; Exer | 1989 |
The role of alpha 1- and alpha 2-adrenergic receptors in mediation of coronary vasoconstriction in hypoperfused ischemic myocardium during exercise.
Topics: Animals; Coronary Circulation; Coronary Disease; Dioxanes; Dogs; Female; Hemodynamics; Idazoxan; Mal | 1989 |
Dissociation between reperfusion induced arrhythmias and increases in ventricular alpha 1 receptor density in the anaesthetised rat.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Heart Ventricles; Male; Myocardial Reperfusion Inju | 1989 |
Alpha-blockade for hypertension: indifferent past, uncertain future.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Drug Evaluation; Humans; Hypertension; Prazosi | 1989 |
[Efficacy, tolerance and incidence of risk factors of Alpress in the treatment of arterial hypertension].
Topics: Adult; Aged; Coronary Disease; Delayed-Action Preparations; Drug Evaluation; Female; Humans; Hyperte | 1989 |
Adenosine-induced hyperemia attenuates myocardial ischemia in coronary microembolization in dogs.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Disease; Dogs; Embolism; Microspheres; Myocardium | 1989 |
Ventricular pressure-heart rate product before induction of ischemia as a determinant of the reperfusion-induced accumulation of calcium within myocardium.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Coronary Disease; Cyclic AMP; Guinea Pig | 1987 |
Alpha 1 adrenoceptors in the ischaemic and reperfused myocardium.
Topics: Aerobiosis; Animals; Binding, Competitive; Cell Membrane; Coronary Disease; Kinetics; Male; Myocardi | 1988 |
Clinical pharmacology of vasodilator drugs.
Topics: Adrenergic alpha-Antagonists; Calcium Channel Blockers; Coronary Disease; Humans; Hydralazine; Hyper | 1985 |
Influence of alpha-adrenergic blockade on platelet-mediated thrombosis in stenosed canine coronary arteries.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Flow Velocity; Blood Platelets; Blood Pressure; Coronar | 1985 |
[Reduction of coronary risk factors with selective alpha-blockers. International Doxazosin Symposium. Frankfurt/Main, 7 June 1986].
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Prazosin; Risk | 1986 |
Alpha adrenoceptors and arrhythmias.
Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Catecholamines; Coronary Disease; Guine | 1986 |
Geriatric hypertension: antihypertensive therapy in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blocker | 1987 |
Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
Clinical experience with doxazosin in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Dru | 1988 |
Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 1988 |
A symposium: Doxazosin: coronary artery disease risk factor management. June 7, 1986, Frankfurt, Germany.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk | 1987 |
Doxazosin: A distinctive approach to risk reduction of coronary heart disease in hypertensive patients. Proceedings of a symposium. Hamburg, West Germany, January 30, 1988.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1988 |
The protective effect of prazosin on the ischaemic and reperfused myocardium.
Topics: Adenosine Triphosphate; Animals; Calcium; Coronary Disease; Diltiazem; Male; Myocardial Contraction; | 1985 |
Electrophysiologic effects of prazosin during acute myocardial ischemia.
Topics: Animals; Coronary Disease; Dogs; Electrophysiology; Male; Prazosin; Receptors, Adrenergic, alpha; Ve | 1986 |
[The status of prazosin in therapy of chronic heart failure].
Topics: Cardiomyopathy, Dilated; Coronary Disease; Drug Therapy, Combination; Heart Failure; Heart Valve Dis | 1988 |
Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Coronary Disease; Heart Rate; Male; Myocard | 1988 |
Delayed myocardial ischemia following the cessation of sympathetic stimulation.
Topics: Animals; Coronary Disease; Dogs; Electric Stimulation; Hemodynamics; Nifedipine; Prazosin; Stellate | 1988 |
Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Captopril; Cardiomyopathy, Dilated; Coronary Disease; Female; Heart Failure; Hemodynami | 1986 |
An experimental approach to the choice of antiarrhythmic therapy.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Diltiazem | 1986 |
Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Coronary Disease; Die | 1986 |
The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Disease M | 1985 |